Posted inBiotechnology
Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi’s potential
Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate…
Posted inBiotechnology
Immuneering touts 64% 1-year survival, keeping wheels turning in race with Revolution
Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival (OS)…
Posted inBiotechnology
Lilly buys inflammation biotech Venytx for $1.2B in wake of Parkinson’s, CV readouts
Ventyx Biosciences has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to…
Posted inBiotechnology
Surgical Specimen Management Enhanced by Information System
In an exciting advancement for operating room efficiency, a recent quasi-experimental study has shed light on the transformative impact of…
Posted inBiotechnology
Mourning Mama: Unmet Care Needs in Maternal Health
In the poignant narrative that resonates deeply within the realm of healthcare, author A. Herrera tackles a pressing and often…
Posted inBiotechnology
Revolutionizing Research: Organoid Analytical Toolkits Unveiled
In recent years, the field of biomedical research has been dramatically transformed through the advent of three-dimensional (3D) cell culture…
Posted inBiotechnology
Impact of Post-Acute Care on Hospital Readmissions
In an era where healthcare systems are grappling with rising costs and the complex needs of patients recovering from acute…
Posted inBiotechnology
Transforming Auto Industry with Advanced Decision Support Systems
The automobile industry has long been recognized as a vital sector of the global economy, contributing significantly to technological advancements,…
Posted inBiotechnology
RNA Polymerase Evolution Accelerated Through Homologous Recombination
In the realm of synthetic biology, the quest to engineer DNA polymerases capable of synthesizing novel or noncognate nucleic acids…
Posted inBiotechnology
Tislelizumab-Lenvatinib Shows Promise for High-Risk Liver Cancer
In a groundbreaking advance that could redefine the therapeutic landscape for liver cancer, a new single-arm phase II clinical trial…